Recent Development News: Q1 – 2016

Centrexion Therapeutics Expands Pain Pipeline with Acquisition of Three New Analgesic Candidates from Boehringer Ingelheim

March 30, 2016 07:00 AM Eastern Daylight Time BALTIMORE­­(BUSINESS WIRE)­­Centrexion Therapeutics, a company focused on advancing chronic pain treatment with new non­opioid and non­surgical therapies, today announced the expansion of its proprietary pipeline with the acquisition of three new analgesic … Continue reading

Posted in Recent Development News: Q1 - 2016, Recent Developments | Comments Off

ContraFect to Present CF-301 Phase 1 Trial Data at the 26th ECCMID Conference

YONKERS, NY–(Marketwired – March 29, 2016) – ContraFect Corporation (NASDAQ:CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that it will present new clinical data … Continue reading

Posted in Recent Development News: Q1 - 2016, Recent Developments | Comments Off

root9B Awarded Air Force Applied Cyber Operations Training Contract

COLORADO SPRINGS, Colo., March 23, 2016 /PRNewswire/ ‑‑ root9B, a root9B Technologies Company (OTCQB: RTNB), and leading provider of advanced cybersecurity services and training for commercial and government clients, announced today it has been awarded a cyber operations training contract … Continue reading

Posted in Recent Development News: Q1 - 2016, Recent Developments | Comments Off

Update: root9B Technologies Receives $7.7 Million in Financing

NEW YORK, March 14, 2016 /PRNewswire/ ‑‑ root9B Technologies (OTCQB: RTNB), a leading provider of Cybersecurity and Regulatory Risk Mitigation Services, announced the closing of a $7.7 million equity sale. The financing concluded on March 10, 2016 with a $5.5 … Continue reading

Posted in Recent Development News: Q1 - 2016, Recent Developments | Comments Off